Researchers in the st. Louis area played a key role in developing anti-inflammatory medications such as Celebrex and other drugs for Pharmacia Corp. before New York-based Pfizer Inc. acquired the company in 2003. Pfizer maintained research operations in St. Louis after the purchase because of the city's reputation as a center for developing biologies, including growth hormones and inhaled insulin, and small-molecule medicines used to treat arthritis, chronic obstructive pulmonary dis-ease and respiratory diseases, according to Edward Bryant, Pfizer's senior adviser of public affairs.
展开▼
